This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
catalog :
156-B7-100
quantity :
100 ug (also 1 mg)
price :
413 USD
citations: 33
Reference
Wu B, Huang X, Shi X, Jiang M, Liu H, Zhao L. LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer. Mol Cancer. 2024;23:184 pubmed publisher
Darwish I, Alahmad W, Vinoth R. Novel ultrasensitive automated kinetic exclusion assay for measurement of plasma levels of soluble PD-L1, the predictive and prognostic biomarker in cancer patients treated with immune checkpoint inhibitors. Heliyon. 2024;10:e31317 pubmed publisher
Jeong H, Koh J, Kim S, Song S, Lee S, Jeon Y, et al. Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. Br J Cancer. 2024;131:23-36 pubmed publisher
Straube J, Bukhari S, Lerrer S, Winchester R, Henick B, Dragovich M, et al. PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. bioRxiv. 2023;: pubmed publisher
Manna L, Rapuano Lembo R, Yoshioka A, Nakamura K, Passariello M, De Lorenzo C. A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies. Cancers (Basel). 2023;15: pubmed publisher
Carter R, Alanazi F, Sharp A, Roman J, Luchini A, Liotta L, et al. Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling. J Biol Chem. 2023;299:105353 pubmed publisher
Rattanapisit K, Bulaon C, Strasser R, Sun H, Phoolcharoen W. In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody. Sci Rep. 2023;13:14146 pubmed publisher
Lorenzini T, Cadilha B, Obeck H, Benmebarek M, M xe4 rkl F, Michaelides S, et al. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer. 2023;129:696-705 pubmed publisher
Coulet M, Lachkar S, Leduc M, Trombe M, Gouveia Z, Perez F, et al. Identification of Small Molecules Affecting the Secretion of Therapeutic Antibodies with the Retention Using Selective Hook (RUSH) System. Cells. 2023;12: pubmed publisher
Munoz O, Banga R, Schelling R, Procopio F, Mastrangelo A, Nortier P, et al. Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. PLoS Pathog. 2022;18:e1010673 pubmed publisher
Gao Q, Wang S, Li F, Lian J, Cheng S, Yue D, et al. High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. Cancer Immunol Res. 2022;10:844-855 pubmed publisher
Curnock A, Bossi G, Kumaran J, Bawden L, Figueiredo R, Tawar R, et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI Insight. 2021;6: pubmed publisher
Bhaskaran N, Schneider E, Faddoul F, Paes da Silva A, Asaad R, Talla A, et al. Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection. Nat Commun. 2021;12:5143 pubmed publisher
Mao C, Wang S, Su Y, Tseng S, He L, Wu A, et al. Protein detection in blood with single-molecule imaging. Sci Adv. 2021;7: pubmed publisher
Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Zambrano N, De Lorenzo C. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers (Basel). 2021;13: pubmed publisher
Ogishi M, Yang R, Aytekin C, Langlais D, Bourgey M, Khan T, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med. 2021;: pubmed publisher
Jin J, Kim C, Xia Q, Gould T, Cao W, Zhang H, et al. Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals. Sci Immunol. 2021;6: pubmed publisher
Huetter J, Gritzan U, Gutcher I, Doecke W, Luetke Eversloh M, Golfier S, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020;8:895-911 pubmed publisher
Sun L, Li C, Chung E, Yang R, Kim Y, Park A, et al. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Res. 2020;80:2298-2310 pubmed publisher
Cembrola B, Ruzza V, Troise F, Esposito M, Sasso E, Cafaro V, et al. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Biomed Res Int. 2019;2019:6051870 pubmed publisher
Carpenter K, Valfort A, Steinauer N, Chatterjee A, Abuirqeba S, Majidi S, et al. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer. Sci Rep. 2019;9:19530 pubmed publisher
Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10:4355 pubmed publisher
Fierle J, Abram Saliba J, Brioschi M, deTiani M, Coukos G, Dunn S. Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery. Sci Rep. 2019;9:12815 pubmed publisher
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3: pubmed publisher
Vogl U, Ohler L, Rasic M, Frischer J, Modak M, Stockl J. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. Anticancer Res. 2017;37:1947-1955 pubmed
Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, et al. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. Mol Cancer Ther. 2017;16:861-870 pubmed publisher
Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
Liu X, Wu X, Cao S, Harrington S, Yin P, Mansfield A, et al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Sci Rep. 2016;6:36722 pubmed publisher
Li J, Jie H, Lei Y, Gildener Leapman N, Trivedi S, Green T, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75:508-518 pubmed publisher
Melendreras S, Martínez Camblor P, Menéndez A, Bravo Mendoza C, González Vidal A, Coto E, et al. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE. 2014;9:e113396 pubmed publisher
Chinnadurai R, Copland I, Patel S, Galipeau J. IDO-independent suppression of T cell effector function by IFN-?-licensed human mesenchymal stromal cells. J Immunol. 2014;192:1491-501 pubmed publisher
Steidl C, Shah S, Woolcock B, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377-81 pubmed publisher
Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol. 2006;177:8844-50 pubmed
product information
master code :
156-B7
SKU :
156-B7-100
product name :
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
unit size :
100 ug (also 1 mg)
description :
The Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
PD-L1/B7-H1
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS and NaCl.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.
species :
Human
observed molecular weight :
70-75 kDa, reducing conditions
theoretical molecular weight :
52 kDa (monomer)
gene symbol :
CD274
details of functionality :
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 ╡g/mL.
endotoxin note :
<0.01 EU per 1 ╡g of the protein by the LAL method.
accessionNumbers :
Q9NZQ7
applications :
Bioactivity
source long :
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein Human PD-L1 (Phe19-Thr239) Accession # Q9NZQ7 DIEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
source short :
NS0
extended description :
Analyzed by SEC-MALS
USD :
413 USD
product details :
Analyzed by SEC-MALS
alt names :
Avelumab, B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274, CD274 antigenMGC142294, CD274 molecule, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.